NCT00276783: Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patient must have progressed after receiving prior whole-brain radiotherapy
Exclusions: Patients with more than 2 prior chemotherapeutic agents or regimens (including biological agents)

Comments are closed.

Up ↑